Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance
Journal of Clinical and Experimental Hematopathology · 2016 · 56 (2) · 89-99
DOI: 10.3960/jslrt.56.89 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2016. Verfasst von Akihiro Tomita. Beteiligte Einrichtung: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine.
Zitieren
APA
Tomita, A. (2016). Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. Journal of Clinical and Experimental Hematopathology, 56(2), 89-99. https://doi.org/10.3960/jslrt.56.89
Vancouver
Tomita A. Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. Journal of Clinical and Experimental Hematopathology. 2016;56(2):89-99. doi:10.3960/jslrt.56.89
BibTeX
@article{Tomita2016,
author = {Tomita, Akihiro},
title = {Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2016},
volume = {56},
number = {2},
pages = {89--99},
doi = {10.3960/jslrt.56.89}
}
EUVIMED